Literature DB >> 23046598

The use of cell-sheet technique eliminates arrhythmogenicity of skeletal myoblast-based therapy to the heart with enhanced therapeutic effects.

Takuya Narita1, Yasunori Shintani, Chiho Ikebe, Masahiro Kaneko, Narumi Harada, Nomathamsanqa Tshuma, Kunihiko Takahashi, Niall G Campbell, Steven R Coppen, Kenta Yashiro, Yoshiki Sawa, Ken Suzuki.   

Abstract

BACKGROUND: Clinical application of skeletal myoblast transplantation has been curtailed due to arrhythmogenicity and inconsistent therapeutic benefits observed in previous studies. However, these issues may be solved by the use of a new cell-delivery mode. It is now possible to generate "cell-sheets" using temperature-responsive dishes without artificial scaffolds. This study aimed to validate the safety and efficacy of epicardial placement of myoblast-sheets (myoblast-sheet therapy) in treating heart failure. METHODS AND
RESULTS: After coronary artery ligation in rats, the same numbers of syngeneic myoblasts were transplanted by intramyocardial injection or cell-sheet placement. Continuous radio-telemetry monitoring detected increased ventricular arrhythmias, including ventricular tachycardia, after intramyocardial injection compared to the sham-control, while these were abolished in myoblast-sheet therapy. This effect was conjunct with avoidance of islet-like cell-cluster formation that disrupts electrical conduction, and with prevention of increased arrhythmogenic substrates due to exaggerated inflammation. Persistent ectopic donor cells were found in the lung only after intramyocardial injection, strengthening the improved safety of myoblast-sheet therapy. In addition, myoblast-sheet therapy enhanced cardiac function, corresponding to a 9.2-fold increase in donor cell survival, compared to intramyocardial injection. Both methods achieved reduced infarct size, decreased fibrosis, attenuated cardiomyocyte hypertrophy, and increased neovascular formation, in association with myocardial upregulation of a group of relevant molecules. The pattern of these beneficial changes was similar between two methods, but the degree was more substantial after myoblast-sheet therapy.
CONCLUSION: The cell-sheet technique enhanced safety and therapeutic efficacy of myoblast-based therapy, compared to the current method, thereby paving the way for clinical application.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bioengineering technology; Cell-based therapy; Cell-sheet technique; Heart failure; Intramyocardial injection; Ventricular arrhythmia

Mesh:

Year:  2012        PMID: 23046598     DOI: 10.1016/j.ijcard.2012.09.081

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  21 in total

1.  Construction of a Multilayered Mesenchymal Stem Cell Sheet with a 3D Dynamic Culture System.

Authors:  Yingwei Wang; Cheng Lu; Chengzhi He; Baoxin Chen; Youling Zheng; Junming Zheng; Jianhua Zhang; Zheng Wu
Journal:  J Vis Exp       Date:  2018-10-20       Impact factor: 1.355

Review 2.  Fate choice of post-natal mesoderm progenitors: skeletal versus cardiac muscle plasticity.

Authors:  Domiziana Costamagna; Mattia Quattrocelli; Robin Duelen; Vardine Sahakyan; Ilaria Perini; Giacomo Palazzolo; Maurilio Sampaolesi
Journal:  Cell Mol Life Sci       Date:  2013-08-15       Impact factor: 9.261

3.  New model for cardiomyocyte sheet transplantation using a virus-cell fusion technique.

Authors:  Yuto Takahashi; Daihachiro Tomotsune; Sakiko Takizawa; Fengming Yue; Mika Nagai; Tadayuki Yokoyama; Kanji Hirashima; Katsunori Sasaki
Journal:  World J Stem Cells       Date:  2015-06-26       Impact factor: 5.326

4.  Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart.

Authors:  Satoshi Kainuma; Shigeru Miyagawa; Satsuki Fukushima; James Pearson; Yi Ching Chen; Atsuhiro Saito; Akima Harada; Motoko Shiozaki; Hiroko Iseoka; Tadashi Watabe; Hiroshi Watabe; Genki Horitsugi; Mana Ishibashi; Hayato Ikeda; Hirotsugu Tsuchimochi; Takashi Sonobe; Yutaka Fujii; Hisamichi Naito; Keiji Umetani; Tatsuya Shimizu; Teruo Okano; Eiji Kobayashi; Takashi Daimon; Takayoshi Ueno; Toru Kuratani; Koichi Toda; Nobuyuki Takakura; Jun Hatazawa; Mikiyasu Shirai; Yoshiki Sawa
Journal:  Mol Ther       Date:  2014-11-25       Impact factor: 11.454

5.  Autologous Skeletal Myoblast Sheet Therapy for Porcine Myocardial Infarction Without Increasing Risk of Arrhythmia.

Authors:  Yutaka Terajima; Tatsuya Shimizu; Shinpei Tsuruyama; Hidekazu Sekine; Hikaru Ishii; Kenji Yamazaki; Nobuhisa Hagiwara; Teruo Okano
Journal:  Cell Med       Date:  2013-10-21

6.  Angiogenic stem cell delivery platform to augment post-infarction neovasculature and reverse ventricular remodeling.

Authors:  Hye Sook Shin; Akshara Thakore; Yuko Tada; Albert J Pedroza; Gentaro Ikeda; Ian Y Chen; Doreen Chan; Kevin J Jaatinen; Shin Yajima; Eric M Pfrender; Masashi Kawamura; Phillip C Yang; Joseph C Wu; Eric A Appel; Michael P Fischbein; YJoseph Woo; Yasuhiro Shudo
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

7.  Extending flaps lifts an infarcted heart toward repair.

Authors:  Gianni Angelini; Massimo Caputo; Paolo Madeddu
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

8.  Epicardial placement of mesenchymal stromal cell-sheets for the treatment of ischemic cardiomyopathy; in vivo proof-of-concept study.

Authors:  Nobuko Tano; Takuya Narita; Masahiro Kaneko; Chiho Ikebe; Steven R Coppen; Niall G Campbell; Manabu Shiraishi; Yasunori Shintani; Ken Suzuki
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

9.  Alternatively activated macrophages determine repair of the infarcted adult murine heart.

Authors:  Manabu Shiraishi; Yasunori Shintani; Yusuke Shintani; Hidekazu Ishida; Rie Saba; Atsushi Yamaguchi; Hideo Adachi; Kenta Yashiro; Ken Suzuki
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

Review 10.  Bone marrow-derived mesenchymal stem cells for the treatment of heart failure.

Authors:  Takuya Narita; Ken Suzuki
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.